UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000003006
Receipt number R000003640
Scientific Title Prospective, randomized, open-label, clinical trial comparing the different Sufonyl Urea(SU) combination with DPP4 inhibitor
Date of disclosure of the study information 2010/01/09
Last modified on 2015/01/09 10:58:20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prospective, randomized, open-label, clinical trial comparing the different Sufonyl Urea(SU) combination with DPP4 inhibitor

Acronym

Prospective, randomized, open-label, clinical trial comparing the different Sufonyl Urea(SU) combination with DPP4 inhibitor

Scientific Title

Prospective, randomized, open-label, clinical trial comparing the different Sufonyl Urea(SU) combination with DPP4 inhibitor

Scientific Title:Acronym

Prospective, randomized, open-label, clinical trial comparing the different Sufonyl Urea(SU) combination with DPP4 inhibitor

Region

Japan


Condition

Condition

Diabetes Mellitus

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Evaluation of efficacy of different Sulfonylurea using cobination with DPP4

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase IV


Assessment

Primary outcomes

Diabetic Control (HbA1c, 1,5AG)
beta cell function (proinsulin/ insulin ratio, CPR index)

Key secondary outcomes

systolic BP, diastolic BP
LDL-cho, HDL-cho, TG


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

4

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

after using gliclazide for 3 months, then substitute to glibenclamide

Interventions/Control_2

after using glibenclamide for 3 months,then substitute to gliclazide

Interventions/Control_3

after glimepiride for 3 months, then substitute to gliclazide

Interventions/Control_4

after gliclazide for 3 months, then substitute to glimepiride

Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

Type2 Diabetes initiated to use sitagliptin(DPP4 inhibitor)
and
mean HbA1c 6.5%-7.5% for 3months
and
when gliclazide, daily dose within 40mg
when glimepiride, daily dose within 1 mg
when glibenclamide, daily dose within 1.25 mg

Key exclusion criteria

1.History of hypersensitivity to sulfonyl urea or sitagliptin
2.During the pregnancy and nursing
3. Severe renal dysfunction (serum creatinin>2.0mg/dl)
4. Severe liver dysfunction (AST, ALT>50IU/ml)
5.
6.Inadequate to entry this study

Target sample size

80


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kazuhiko Sakaguchi

Organization

Kobe University Graduate School of Medicine

Division name

Division of Diabetes,Metabolism and Endocrinology, Department of Internal Medicine

Zip code


Address

7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Kazuhiko Sakaguchi

Organization

Kobe University Graduate School of Medicine

Division name

Division of Diabetes,Metabolism and Endocrinology, Department of Internal Medicine

Zip code


Address

7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017

TEL


Homepage URL


Email

kzhkskgc@med.kobe-u.ac.jp


Sponsor or person

Institute

Kobe University Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

神戸大学医学部付属病院(兵庫県)


Other administrative information

Date of disclosure of the study information

2010 Year 01 Month 09 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2010 Year 01 Month 10 Day

Date of IRB


Anticipated trial start date

2011 Year 03 Month 01 Day

Last follow-up date

2012 Year 03 Month 01 Day

Date of closure to data entry

2012 Year 06 Month 01 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2010 Year 01 Month 09 Day

Last modified on

2015 Year 01 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003640


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name